HomeCompareHRGLY vs ABBV

HRGLY vs ABBV: Dividend Comparison 2026

HRGLY yields 4.11% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $22.4K in total portfolio value
10 years
HRGLY
HRGLY
● Live price
4.11%
Share price
$23.55
Annual div
$0.97
5Y div CAGR
31.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$79.9K
Annual income
$19,854.61
Full HRGLY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — HRGLY vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHRGLYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HRGLY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HRGLY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HRGLY
Annual income on $10K today (after 15% tax)
$349.38/yr
After 10yr DRIP, annual income (after tax)
$16,876.42/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $4,179.59/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HRGLY + ABBV for your $10,000?

HRGLY: 50%ABBV: 50%
100% ABBV50/50100% HRGLY
Portfolio after 10yr
$91.1K
Annual income
$22,313.18/yr
Blended yield
24.48%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

HRGLY
Analyst Ratings
2
Hold
Consensus: Hold
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HRGLY buys
0
ABBV buys
0
No recent congressional trades found for HRGLY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHRGLYABBV
Forward yield4.11%3.06%
Annual dividend / share$0.97$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR31.8%40.6%
Portfolio after 10y$79.9K$102.3K
Annual income after 10y$19,854.61$24,771.77
Total dividends collected$53.1K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: HRGLY vs ABBV ($10,000, DRIP)

YearHRGLY PortfolioHRGLY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,242$541.75$11,550$430.00$308.00ABBV
2$12,779$750.18$13,472$627.96$693.00ABBV
3$14,724$1,050.40$15,906$926.08$1.2KABBV
4$17,245$1,490.78$19,071$1,382.55$1.8KABBV
5$20,603$2,150.78$23,302$2,095.81$2.7KABBV
6$25,211$3,165.13$29,150$3,237.93$3.9KABBV
7$31,746$4,770.58$37,536$5,121.41$5.8KABBV
8$41,368$7,399.60$50,079$8,338.38$8.7KABBV
9$56,141$11,877.19$69,753$14,065.80$13.6KABBV
10$79,925$19,854.61$102,337$24,771.77$22.4KABBV

HRGLY vs ABBV: Complete Analysis 2026

HRGLYStock

Hargreaves Lansdown plc provides investment services for individuals and corporates in the United Kingdom and Poland. It primarily operates Vantage, a direct-to-investor platform. The company offers stocks and shares individual savings accounts (ISAs), fund and share accounts, and junior and lifetime ISAs. It also provides pension services, including self-invested personal pensions (SIPP), junior SIPPs, annuities, and drawdown; share dealing services; and fund dealing services. In addition, the company offers investment accounts; cash savings; foreign currency exchange services; and financial advisory services. Hargreaves Lansdown plc was founded in 1981 and is headquartered in Bristol, the United Kingdom.

Full HRGLY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this HRGLY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HRGLY vs SCHDHRGLY vs JEPIHRGLY vs OHRGLY vs KOHRGLY vs MAINHRGLY vs JNJHRGLY vs MRKHRGLY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.